← Back to Search

Thrombolytic Agent

Alteplase for Empyema

N/A

Waitlist Available

Led By Jeana D O'Brien, MD, FACP, FCCP

Research Sponsored by O'Brien, Jeana D., MD, FACP, FCCP

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Age greater or equal to 18 yrs

Presence of empyema or CPE

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 5 years

Awards & highlights

Study Summary

This trial is studying two different dose strategies of Alteplase to see if it is more effective than placebo in treating patients with empyema or complicated parapneumonic effusion.

Who is the study for?

This trial is for adults 18 years or older with empyema (pus in the space between the lungs and chest wall) or complicated parapneumonic effusion (fluid around the lungs). Participants must be able to consent. Those with bleeding disorders, active internal bleeding, pregnancy, previous study enrollment, low platelet counts, certain anticoagulant use, Alteplase allergies or neurological disorders cannot join.Check my eligibility

What is being tested?

The study is testing how well patients with empyema or CPE respond to different dosing schedules of Alteplase—a medication that breaks down blood clots—compared to a saline placebo. One group receives it daily while another twice daily; both are measured against a control group receiving saline.See study design

What are the potential side effects?

Alteplase can cause side effects such as bleeding problems due to its clot-dissolving action. There might also be allergic reactions in those sensitive to the drug and potential irritation at the injection site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Select...

I have fluid in my chest due to infection or inflammation.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Need for surgical intervention via thoracostomy or open decortication as a result of conservative therapy.

Secondary outcome measures

Daily chest tube drainage

Hospital length of stay

Mortality

+1 more

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Texas A&M UniversityOTHER

140 Previous Clinical Trials

24,031 Total Patients Enrolled

O'Brien, Jeana D., MD, FACP, FCCPLead Sponsor

Genentech, Inc.Industry Sponsor

1,540 Previous Clinical Trials

567,824 Total Patients Enrolled

1 Trials studying Empyema

100 Patients Enrolled for Empyema

Media Library

Alteplase (Thrombolytic Agent) Clinical Trial Eligibility Overview. Trial Name: NCT00103766 — N/A

Empyema Clinical Trial 2023: Alteplase Highlights & Side Effects. Trial Name: NCT00103766 — N/A

Alteplase (Thrombolytic Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00103766 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Who qualifies to participate in this clinical investigation?

"This empyema study is looking for 75 participants aged 18 or older. To be eligible, applicants must meet the following criteria: minimum age of eighteen years old."

Answered by AI

Is this experiment recruiting new participants?

"According to clinicaltrials.gov, this trial is not currently looking for participants; the initial post was made on October 1st 2004 and last edited July 31 2006. Nevertheless, 33 other trials are actively seeking patients at this moment in time."

Answered by AI